Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Parenteral nutrition for patients requiring supplemental or total nutritional support,Off-label: Not typically used off-label due to specific formulation
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Amino acids are metabolized via transamination and deamination in the liver; dextrose undergoes glycolysis and enters the citric acid cycle. Electrolytes are excreted or reabsorbed renally.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Amino acids: negligible (<5% bound). Dextrose: negligible. Electrolytes: variable; calcium ~40% bound to albumin, magnesium ~30% bound to albumin, potassium and sodium minimally bound (<5%).
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Amino acids: total body water (~0.5-0.7 L/kg). Dextrose: total body water (~0.2 L/kg initially). Electrolytes: sodium ~0.6 L/kg, potassium ~0.4 L/kg, calcium ~0.2 L/kg, magnesium ~0.3 L/kg.
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
Not applicable; administered as intravenous infusion only (bioavailability 100% by IV route). No oral bioavailability.
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
In GFR 30-59 m L/min: reduce amino acid dose by 50% and monitor electrolytes closely. If GFR <30 m L/min: avoid or use only with extreme caution, typically restrict protein to 0.6-0.8 g/kg/day and adjust electrolytes per serum levels.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
Child-Pugh Class A: no adjustment necessary. Child-Pugh B: reduce amino acid dose to 0.8-1.2 g/kg/day. Child-Pugh C: avoid due to risk of encephalopathy; if essential, restrict to 0.5-0.7 g/kg/day with branched-chain amino acid enrichment.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Neonates and infants: 2-3 g/kg/day amino acids and 10-15 g/kg/day dextrose, titrating gradually. Children: 1-2 g/kg/day amino acids and 5-10 g/kg/day dextrose; rate not to exceed 0.2-0.4 g/kg/h dextrose. Adjust electrolytes per daily requirements.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Elderly patients: start at lower end of dose range; monitor renal function and serum electrolytes closely. Typical amino acid dose 1.0-1.2 g/kg/day, dextrose dose adjusted to avoid hyperglycemia; infusion rate not to exceed 2 mg/kg/min.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
Not for use in patients with severe electrolyte imbalances, severe liver disease, or severe renal impairment. May cause hyperglycemia, electrolyte abnormalities, or volume overload. Must be used under medical supervision.
None.
Monitor serum glucose, electrolytes, fluid status, and renal function,Risk of hyperglycemia in diabetic patients,Risk of electrolyte disturbances including hyperkalemia, hypercalcemia, and hyperphosphatemia,Avoid in patients with galactosemia or fructose intolerance,Use caution in hepatic or renal impairment
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Hypersensitivity to any component,Severe electrolyte imbalance,Severe liver disease (e.g., hepatic coma),Severe renal impairment (anuria, oliguria),Galactosemia,Fructose intolerance
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
No direct food interactions as this is an intravenous product. However, oral intake may be restricted or monitored due to underlying medical conditions (e.g., diabetes, renal failure). Ensure consistent carbohydrate intake if transitioning to oral feeding.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, amino acids and dextrose are endogenous substances; electrolyte imbalances can cause fetal harm. In first trimester: avoid unless maternal benefit outweighs risk; deficiencies in essential nutrients may be teratogenic. Second/third trimester: use only if clearly needed; monitor for hyperglycemia (risk of fetal macrosomia, neonatal hypoglycemia).
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
Excretion into breast milk: unknown. Components are endogenous, so transfer is likely minimal. No specific M/P ratio available. Considered probably compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal levels are abnormal.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Pregnancy requires increased nutritional demands; no specific dose adjustments are established. Monitor blood glucose due to insulin resistance; consider reducing dextrose infusion if hyperglycemia develops. Adjust electrolytes based on serial monitoring. Start at lower infusion rates and titrate slowly.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
CLINIMIX E 2.75/25 is a dual-chamber bag containing amino acids and dextrose with electrolytes, including calcium. Do not use if seals are broken or if solution is discolored. Must be administered via central line due to high dextrose concentration (25%). Avoid simultaneous administration with ceftriaxone due to calcium-ceftriaxone precipitation risk. Monitor serum electrolytes, blood glucose, and liver function tests closely. Not for use in patients with severe hepatic or renal impairment.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This medication provides nutrition through a vein and must be given by a healthcare professional.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, itching, difficulty breathing).,Inform your healthcare provider if you have a history of diabetes, kidney disease, or liver problems.,This solution contains added calcium; avoid taking additional calcium supplements without doctor approval.,You may experience changes in blood sugar; symptoms of high or low blood sugar (e.g., excessive thirst, urination, shakiness) should be reported.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSOL 5%, answered by our medical review team.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.